Notably, a recent clinical trial also showed that sparsentan, a non-immunosuppressive, dual endothelin and angiotensin receptor antagonist with high selectivity for ETAR and AT1,R is highly effective in IgA nephropathy (57). The gene discussed is EDNRA; the disease is IgA glomerulonephritis.